ARKG vs XBI
ARK Genomic Revolution ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.75% for ARKG.
- • XBI pays a higher dividend yield (0.34%).
Side-by-side metrics
| Metric | ARKG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $1.24B | $8.30B |
YTD return | 7.21% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.35 | 1.09 |
P/E ratio | — | — |
Last price | $30.38 | $133.66 |
Inception | — | — |
Issuer | ARK | State Street |
ARKG top holdings
| TEM | Tempus AI Inc Class A common stock | 9.45% |
| TWST | Twist Bioscience Corp | 9.02% |
| CRSP | CRISPR Therapeutics AG | 8.94% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 5.78% |
| BEAM | Beam Therapeutics Inc | 5.44% |
| ABSI | Absci Corp | 4.79% |
| NTRA | Natera Inc | 4.08% |
| ILMN | Illumina Inc | 4.04% |
| NTLA | Intellia Therapeutics Inc | 3.83% |
| PSNL | Personalis Inc | 3.59% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Tempus AI Inc Class A common stock (TEM), which represents 9.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.